Below are a few of the many newly approved products as featured on DocWire News. The U. Read More. Food and Drug Administration approved caplacizumab-yhdp CABLIVI injection as the first treatment specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura aTTP in combination with plasma exchange and immunosuppressive therapy.
Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer
FDA Approves Breast Cancer Immunotherapy Treatment Tecentriq
Balversa erdafitinib ; Janssen Oncology; For the treatment of locally advanced or metastatic urothelial carcinoma , Approved April Bavencio avelumab plus Inlyta axitinib ; Merck and Pfizer; For the first line treatment of advanced renal cell carcinoma, Approved May Inrebic fedratinib ; Celgene; For the treatment of myelofibrosis, Approved August Keytruda pembrolizumab ; Merck; previously treated metastatic small cell lung cancer, Approved June Keytruda pembrolizumab ; Merck; For the treatment of advanced renal cell carcinoma, Approved April Nubeqa darolutamide ; Bayer; For the treatment of non-metastatic castration-resistant prostate cancer, Approved July Polivy polatuzumab vedotin-piiq ; Genentech; For the treatment of diffuse large B-cell lymphoma, Approved June
Forgot Password? Sign Up. Quick Links. Case Study: Albuterol.
The U. Food and Drug Administration FDA has just approved a new drug called alpelisib also known by its brand name, Piqray , which could be a game changer for patients with a specific type of advanced or metastatic breast cancer. A PI3K inhibitor is a drug that works by blocking the PI3K phosphoinositide 3-kinase enzyme, which has an essential function in allowing cells—including cancer cells—to grow. Piqray was specifically approved for use in combination with the endocrine therapy fulvestrant.